Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 23 April 2014 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) is getting some new, though not unexpected, authority this week by way of its parent organization, the US Department of Health and Human Services (DHHS).
The new authority pertains to a new law passed in 2013 known as the Drug Quality and Security Act (DQSA), which was passed in the wake of a deadly scandal involving pharmaceutical products compounded using deficient practices. Part of the law permitted FDA to more tightly regulate some-but not all-of the compounding pharmacies.
It also called for it to establish more regular communications with state boards of pharmacy, which continue to oversee the bulk of the small-scale compounding operations, such as those found in hospitals.
In particular, Section 105 of the act, Enhanced Communication, calls for FDA to "receive submissions from state boards of pharmacy describing actions taken against compounding pharmacies … or expressing concerns that a compounding pharmacy may be acting contrary to section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act)."
For example, FDA and state boards of pharmacy might communicate about Warning Letters, sanctions, penalties, violations, revoked licenses, registration violations or other problems.
There was just one minor problem: The law called for the communications to go through the "Secretary"-that is, the secretary of DHHS.
But on 22 April 2014, DHHS transferred this authority to FDA in a "delegation of authorities" notice published in the Federal Register.
Henceforth, FDA has the authority to communicate on its own behalf with state boards of pharmacy under Section 105 of the DQSA, and all prior communications are retroactively made official as well.
The new authority should make it somewhat-though not substantially-easier for FDA to communicate with its state-level regulatory counterparts around the country.
DHHS Federal Register Notice
Tags: Delegated Authority, DQSA, Pharmaceutical Compounding, Compounding, Latest News, Authority, DHHS
Regulatory Focus newsletters
All the biggest regulatory news and happenings.